What is the management approach for alcohol withdrawal using Clinical Institute Withdrawal Assessment (CIWA) scoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Alcohol Withdrawal Using CIWA Scoring

Benzodiazepines administered using a symptom-triggered approach based on CIWA-Ar scoring is the gold standard treatment for alcohol withdrawal syndrome, with long-acting benzodiazepines preferred for most patients and short-acting options for those with hepatic dysfunction or elderly patients. 1, 2

Assessment and Severity Classification Using CIWA-Ar

  • The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) is the standard tool for evaluating withdrawal severity:

    • Score <8: Mild withdrawal - observation only
    • Score 8-14: Moderate withdrawal - requires medication
    • Score ≥15: Severe withdrawal - requires aggressive treatment 1, 2
  • CIWA-Ar assesses 10 symptoms including nausea/vomiting, tremor, sweating, anxiety, agitation, tactile/visual/auditory disturbances, headache, and orientation

  • Important: CIWA-Ar should not be used alone for diagnosis as high scores may also occur in anxiety disorders, sepsis, hepatic encephalopathy, and severe pain 2

Treatment Algorithm Based on CIWA-Ar Scores

  1. Mild Withdrawal (CIWA-Ar <8):

    • Monitor every 4-8 hours
    • No pharmacological intervention needed
    • Ensure adequate hydration and electrolyte balance
  2. Moderate Withdrawal (CIWA-Ar 8-14):

    • Implement symptom-triggered benzodiazepine protocol
    • Reassess CIWA-Ar score every 2-4 hours
    • Can be managed in outpatient setting with close monitoring
  3. Severe Withdrawal (CIWA-Ar ≥15):

    • Immediate benzodiazepine administration
    • Reassess CIWA-Ar score every 1-2 hours
    • Inpatient management required, especially with history of withdrawal seizures or delirium tremens 2

Benzodiazepine Selection and Dosing

  • First-line options:

    • Long-acting benzodiazepines (preferred for most patients):

      • Diazepam: 5-10 mg PO/IV every 6-8 hours
      • Chlordiazepoxide: 25-100 mg PO every 4-6 hours
    • Short/intermediate-acting benzodiazepines (for elderly, hepatic dysfunction):

      • Lorazepam: 1-4 mg PO/IV/IM every 4-8 hours
      • Oxazepam: 15-30 mg PO every 6-8 hours 1, 2
  • Symptom-triggered protocol:

    • Administer benzodiazepines based on CIWA-Ar scores
    • Results in lower total medication doses and shorter treatment duration compared to fixed-schedule dosing 2
    • Continue until CIWA-Ar scores remain <8 for 24 hours

Essential Adjunctive Therapies

  • Thiamine supplementation:

    • Administer 100-300 mg/day to all AWS patients
    • Continue for 2-3 months following resolution of withdrawal symptoms
    • Prevents Wernicke encephalopathy 2
  • Electrolyte replacement:

    • Correct magnesium, potassium, and phosphate deficiencies
    • Monitor glucose levels and treat hypoglycemia
  • For agitation not controlled by benzodiazepines:

    • Haloperidol: 0.5-5 mg PO/IM every 8-12 hours
    • Note: Antipsychotics should not be used as standalone treatment for AWS 2

Special Considerations

  • Patients with liver disease:

    • Use lorazepam or oxazepam instead of long-acting benzodiazepines
    • Monitor for oversedation and respiratory depression 1
  • Delirium tremens (typically begins 48-72 hours after last drink):

    • Always requires inpatient management, often in ICU
    • Aggressive benzodiazepine treatment
    • IV fluids, electrolyte correction, and thiamine supplementation 2
  • Withdrawal seizures:

    • Benzodiazepines are both treatment and prevention
    • Higher CIWA-Ar scores (>15) predict increased seizure risk 3

Post-Withdrawal Management

  • Consider medications to prevent relapse (acamprosate, naltrexone, disulfiram)
  • Refer to specialized addiction services and support groups
  • Psychiatric consultation for evaluation and long-term planning 2

Monitoring Effectiveness

Studies show that using CIWA-Ar for symptom-triggered treatment results in:

  • Reduced total benzodiazepine doses (mean dose 81.4 vs. 60.3 mg) 4
  • No increase in complications when properly implemented 4, 5
  • Earlier identification of patients at risk for severe withdrawal 3

The CIWA-Ar has been validated across multiple settings and languages, making it a reliable tool for managing alcohol withdrawal syndrome 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.